Positions
Roswell Park Comprehensive Cancer Center
- Professor of Oncology
- Chief, Nuclear Medicine
- Department of Diagnostic and Interventional Radiology
University of Toronto
- Professor, Department of Medical Imaging
Background
Education and Training
- 2020 - PhD- Biomedical Engineering, University of Toronto, Toronto, Ontario
- 2002 - MD - Radiology and Nuclear Medicine, University of Toronto, Toronto, Ontario
- 1997 - BASc - Engineering Science, University of Toronto, Toronto, Ontario
Residency
- 2007 - Radiology, University of Toronto, Toronto, Ontario
- 2009 - Joint Program in Nuclear Medicine, Harvard Medical School, Boston, MA
Fellowship
- 2009 - Oncology/PET, Harvard Medical School, Boston, MA
Board Certification
- American Board of Nuclear Medicine
- American Board of Radiology
- American Board of Nuclear Cardiology
Professional Memberships
- American College of Nuclear Medicine
- American Roentgen Ray Society
- RSNA
- SNMMI
Honors & Awards
- Society of Nuclear Medicine and Molecular Imaging
- Fellow of The American College of Nuclear Medicine
- Lifetime Achievement Award from The American College of Nuclear Medicine
- 2025 Academic Council Tom Millard Memorial Lecture Award from SNMMI
- Honored Educator Award from Radiology Society of North America
- Past President, American College of Nuclear Medicine
- Best Personal Mentor Award from American College of Nuclear Medicine
- Distinguished Educator Award from SNMMI
- Academic Radiologist of the Year Award from McMaster University
Publications
Pediatric Reference Ranges for Glomerular Filtration Rate Determined by a Single Injection of 99mTc-DTPA.Zukotynski KA, Grant FD, Du L, Hsiao E, Zurakowski D, Valencia VF, Treves ST, Fahey FH.J Nucl Med. 2026 Jun 18:jnumed.125.271392. doi: 10.2967/jnumed.125.271392. Online ahead of print.
Summary of the 2024 Update of the North American Guidelines for Pediatric Administered Radiopharmaceutical Activities.
Treves ST, Fahey FH, Valencia VF, Burchell N, Burton C, Czachowski M, Grant FD, Lai H, Lim R, Nadel H, Pampaloni MH, Pandit-Taskar N, Parisi M, Seghers V, Shah S, Shulkin B, States L, Vali R, Yoo D, Zukotynski K.J Nucl Med. 2026 Mar 2;67(3):341-342. doi: 10.2967/jnumed.125.270478.
Summary: Appropriate Use Criteria for 18F-FDG PET/CT for Initial Staging of Malignant Disease.Jadvar H, Atkins MB, Bartel T, de Geus-Oei LF, Dibble EH, Halmos B, Subramaniam RM, Ulaner GA, Vaz SC, Nadel H, Zukotynski K, Griffeth LK.J Nucl Med. 2025 Jul 1;66(7):1034-1038. doi: 10.2967/jnumed.125.270429.
Kuo PH, Esposito G, Ulaner GA, Yoo D, Zukotynski K, Ravizzini GC, Penny R, Miller MP, Chau A, Davis P, Chapin BF, Schuster DM; SPOTLIGHT and LIGHTHOUSE study groups. "Interreader and Intrareader Reproducibility of 18F-Flotufolastat Image Interpretation in Patients with Newly Diagnosed or Recurrent Prostate Cancer: Data from Two Phase 3 Prospective Multicenter Studies", J Nucl Med; 65(8):1239-1243 (2024). PMID: 38871390
Zukotynski K, Black SE, Kuo P, Bhan A, Adamo S, Scott C, Lam B, Masellis M, Kumar S, Fischer CE, Tartaglia MC, Lang AE, Tang-Wai DF, Freedman M, Vasdev N, Gaudet V. “Exploratory Assessment of K-means Clustering to Classify [18F]Flutemetamol Brain PET as Positive or Negative”, Clin Nucl Med; 46(8):616-620 (2021).
Metser U, Zukotynski K, Mak V, Langer D, MacCrostie P, Finelli A, Kapoor A, Chin J, Lavallee LT, Klotz L, Hagerty M, Hildebrand C, Bauman G. “Effect of 18F-DCFPyL PET/CT on the management of patients with recurrent prostate cancer”, Radiology; 303(2):414-422 (2022).
Zukotynski K, Gaudet V, Uribe CF, Mathotaarachchi S, Smith KC, Rosa-Neto P, Benard F, Black SE. “Machine Learning in Nuclear Medicine: Part 2-Neural Networks and Clinical Aspects”, J Nucl Med; 62(1):22-29 (2021).
Uribe CF, Mathotaarachchi S, Gaudet V, Smith KC, Rosa-Neto P, Benard F, Black S, Zukotynski K. “Machine Learning in Nuclear Medicine: Part 1-Introduction”, J Nucl Med; 60(4):451-458 (2019).
Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE. “Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin”. J Clin Oncol. 31(26): 3182-3190 (2013).